The bearish wave draft after Fresenius sold its stakes on Rhoen-Klinikum may upturn near the support line.

Regarding fundamentals, the company that is one of the largest healthcare providers in Germany had a prosperous 2013 year. Its operations increased by 5%, where the acute care business was the main mover for rising numbers. Its undervalued situation with an EPS that represents only 3 times estimated earnings. According to analyst revisions EPS for 2014 is expected at EUR 7.47 per share from EUR 1.10 per share twelve months back, principally due to the sale of 43 hospitals to Fresenius for more than EUR 3 billion.

As regards Surperformance© ratings, Rhoen-Klinikum presents a perfect opportunity for short and midterm trading strategies. The stock approaches an oversold territory giving investors an excellent opportunity for acquire some shares at discounted entry prices. Moreover, almost all moving averages in all-time scales seem to corroborate the likeliness of an upswing toward the EUR 24.7 resistance.

Consequently, the closeness to EUR 23.25 may lure buyers seeking to make some profits in the market trend to come, with a target price at EUR 24.7. However, the breakout through the EUR 24.1 will be the key point to validate the bull run. A stop-loss is recommended under the EUR 23.2 support.